LIMA, Peru – The infection-prevention potential of Lenacapavir,  the long-acting anti-HIV injectable administered just twice a year, took centre stage at the fifth HIV Research for Prevention Conference (HIVR4P) held last week. However, several other important studies were also unveiled, including an injectable that combines contraception and HIV protection, results from a three-month vaginal ring, […] Continue reading ->